항균제 감수성 판정기준에 대한 국제 지침들의 개정 내용 소개
Introduction to the Revised International Guidelines on Breakpoints for Antimicrobial Susceptibility Testing
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
항균제 감수성 시험(antimicrobial susceptibility testing, AST)의 시행과 판독에 대한 지침인 Clinical and Laboratory Standards Institute (CLSI) M100, Performance Standards for AST와 the European Committee on AST (EUCAST) Breakpoint tables for interpretation of minimum inhibitory concentrations and zone diameters은 매년 개정이 이루어진다. 2023년도 CLSI 지침은 antibiotic stewardship 강화의 일환으로 항균제의 선택적 보고와 단계적 보고방법이 도입되었고, Enterobacterales의 aminoglycoside (AG), Pseudomonas aeruginosa의 AG와 piperacillin 계열의 판정기준에 변화가 있었다. EUCAST의 주된 변경 사항은 Enterobacterales에서 aminopenicillin의 판정기준의 변화로, 임상상황 및 항균제 투여방법을 반영한 세분화된 판정기준이 제시되었다.
Abstract
Clinical and Laboratory Standards Institute (CLSI) M100 ‘Performance Standards for Antimicrobial Susceptibility Testing (AST)’ and the European Committee on AST (EUCAST) ‘Breakpoint tables for interpretation of MICs and zone diameters’ guidelines for conducting and interpreting AST are revised yearly. The 2023 CLSI guideline introduces selective and cascade reporting methods for antibacterial agents as a part of strengthening antibiotic stewardship and changes in breakpoints for aminoglycoside (AG) in Enterobacterales and AG and piperacillin in Pseudomonas aeruginosa. Main changes in EUCAST include revised breakpoints for aminopenicillins in Enterobacterales, and detailed criteria reflecting the clinical situation and antibacterial agent administration method.
참고문헌 (10)
- CLSI, "Performance Standards for Antimicrobial Susceptibility Testing. CLSI supplement M100" (2023), Clinical and Laboratory Standards Institute
- 장철훈, "Clinical and Laboratory Standards Institute의 항생제 감수성 검사 소위원회 회의 소개", Annals of Clinical Microbiology, 21(4), pp.69~74 (2018), 대한임상미생물학회
- Sader HS, "Impact of the recent Clinical and Laboratory Standards Institute breakpoint changes on the antimicrobial spectrum of aminoglycosides and the activity of plazomicin against multidrug-resistant and carbapenemresistant Enterobacterales from United States medical centers", Open Forum Infect Dis, 10, pp.ofad058~ (2023)
- Castanheira M, "Activity of plazomicin tested against Enterobacterales isolates collected from U.S. hospitals in 2016-2017: effect of different breakpoint criteria on susceptibility rates among aminoglycosides", Antimicrob Agents Chemother, 64, pp.10~1128 (2020)
- CLSI, "Performance Standards for Antimicrobial Susceptibility Testing. CLSI supplement M100" (2022), Clinical and Laboratory Standards Institute
- "Breakpoint tables for interpretation of MICs and zone diameters. Version 12.0"[URL]
- Yamagishi Y, "Investigation of the clinical breakpoints of piperacillin-tazobactam against infections caused by Pseudomonas aeruginosa", J Infect Chemother, 18, pp.127~129 (2012)
- Wu H, "Selective and cascade reporting of antimicrobial susceptibility testing results and its impact on antimicrobial resistance surveillance-national healthcare safety network, April 2020 to March 2021", Microbiol Spectr, 11, pp.e0164622~ (2023)
- "Breakpoint tables for interpretation of MICs and zone diameters. Version 13.1"[URL]
- de Velde F, "Non-linear absorption pharmacokinetics of amoxicillin : consequences for dosing regimens and clinical breakpoints", J Antimicrob Chemother, 71, pp.2909~2917 (2016)